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1. Introduction
Temporomandibular disorder involves the muscles of mastication, the temporomandibular 
joint (TMJ), and/or associated orofacial structures [42]. Clinical manifestations include 
limited jaw movement, noises or locking in the TMJ, and pain aggravated by jaw function, 
the latter being a necessary criterion for diagnoses of myalgia and TMJ arthralgia [51]. TMD 
affects 6–10% of women and 3% of men in the US population [24,25], making it the most 
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common type of orofacial pain. Chronic TMD produces substantial disability and suffering 
and diminishes quality of life [9]. In addition, it is associated with increased unemployment 
and decreased work effectiveness [11,37,60]. This societal burden potentially could be 
prevented if risk factors for TMD were better understood.
TMD is often comorbid with headache although the estimated degree of overlap varies 
among studies. In a recent analysis of the US National Health Interview Survey, the 
population prevalence of TMD-related pain was much higher among individuals with severe 
headache (15.6%) than those without severe headache (2.6%) [44]. Among patients seeking 
treatment for headache, Korean and Danish studies reported a strikingly high rate of TMD: 
51.6% and 56.1%, respectively [7,27]. While TMD symptoms in a large Brazilian 
population study were more common in individuals with all types of headache compared to 
headache-free people, the highest association was observed with migraine [17]. Similarly, 
several reports confirmed that particular types of headache are frequently comorbid with 
TMD. Specifically, among orofacial pain patients in a US study, 61.3% reported any 
headache and 38% reported migraine with or without aura [10]. In an Italian population-
based study, headache prevalence was significantly higher among individuals with TMD 
relative to TMD-free persons (27.4% vs. 15.2%) [8] while a greater difference was observed 
in a US study that compared TMD patients with general dental patients (72.7% vs. 31.9%) 
[40]. The variability in TMD and headache prevalence rates across studies is likely due to 
methodologic factors such as the methods for ascertaining the diagnostic criteria and sample 
characteristics such as population or clinic settings.
Although many reports demonstrate a relation between headache and TMD, most evidence 
comes from studies using cross-sectional designs which cannot determine a causal relation. 
Only prospective cohort studies offer an opportunity to measure exposure to a hypothesized 
risk factor (in this instance, headache) prior to onset of an index disease (in this case, TMD) 
and therefore establish a temporal sequence between putative cause and effect, necessary for 
confirming causal inference [22]. To overcome limitations of the previous cross-sectional 
reports, the present manuscript used data from the large-scale prospective cohort study of 
first-onset TMD. This study was a part of the project entitled “Orofacial Pain: Prospective 
Evaluation and Risk Assessment” (OPPERA). The objectives of our study were to: 1) 
Describe the prevalence of headache in a community-based sample of U.S. adults at their 
time of enrollment; 2) Evaluate contribution of headache to the risk of developing first-onset 
TMD during prospective follow-up of the participants; and 3) Describe the dynamic patterns 
of headache types at baseline and during follow-up of the participants.
2. Methods
This paper reports findings from the multisite OPPERA project. Institutional Review Boards 
at each OPPERA study site approved the study and each enrollee signed informed consent to 
participate. Study methods have been described in detail elsewhere [6,55,56] and are 
summarized below.
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2.1. Study design and setting
Data in this paper are from two study designs used to investigate incidence of first-onset 
temporomandibular disorder (TMD) in a sample of U.S. adults: 1) the OPPERA prospective 
cohort study enrolled community-based volunteers who had no history of TMD and 
followed them for up to five years in order to identify incident cases of TMD; and 2) the 
OPPERA nested case-control study of TMD incidence collected additional follow-up data 
from those incident cases and from a similar number of controls selected at random from 
members of the prospective cohort study who remained free of TMD.
2.2. Study participants and measurements
The prospective cohort study enrolled 3,263 volunteers between May 2006 and November 
2008 at four U.S. study sites: Baltimore, MD; Buffalo, NY; Chapel Hill, NC; and 
Gainesville, FL. Volunteers were recruited from communities surrounding each study site 
using advertisements, flyers, and email. To be eligible for enrollment, volunteers had to 
satisfy selection criteria determined during telephone screening and at the baseline clinic 
visit.
2.2.1. Telephone screening—Potential participants were interviewed by telephone to 
establish that they met all nine of the following screening eligibility criteria: 1) aged 18–44 
years; 2) no significant history of TMD symptoms; 3) never diagnosed with TMD; 4) no use 
of an occlusal splint during sleep; 5) no recent history of facial injury or surgery; 6) no 
significant medical illnesses; 7) not pregnant or nursing; 8) not receiving orthodontic 
treatment; and 9) <5 headaches per month within each of the preceding three months. The 
latter was determined by asking “Considering headaches of all types in the past 3 months, 
how many headaches on average per month have you had?” People who reported ≥5 
headaches per month were excluded because there was a suspected higher likelihood that 
they would have failed to meet the clinical examination criterion of no significant TMD-
related pain history, described below. Potential study participants who satisfied all screening 
criteria were mailed questionnaires and they were invited to attend their local study site for a 
baseline clinic visit.
2.2.2. Baseline headache questionnaire—One of the mailed questionnaires was the 
Comprehensive Pain Symptom Questionnaire (CPSQ) which asked detailed questions about 
headaches (see Appendix A of [41]). The CPSQ was completed at home, prior to the 
baseline clinic visit, either on paper or online. The three pages of questions about headache 
first asked “In the past year, how many different types of headaches have you had (e.g., 
stress or tension-type, migraine, hunger headache, sinus headache)?” Details of up to three 
different types of headaches were then reported in separate sections. Each section asked 
about location, intensity, characteristics, duration, frequency, and aggravating factors 
associated with each type of headache.
2.2.3. Baseline clinic visit—Trained examiners applied the Research Diagnostic Criteria 
for TMD (RDC/TMD) [12] to exclude anyone who had myalgia and/or arthralgia in the 
masticatory structures. The two criteria required for TMD classification were: 1) history of 
pain in examiner-verified masticatory tissues on ≥5 days of the preceding 30 days; and 2) 
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pain in masticatory tissues evoked by standardized jaw movements or examiner-palpation of 
the masticatory muscles and temporomandibular joints. Also during the visit, participants 
completed questionnaires, underwent quantitative sensory testing, provided cardiovascular 
measures of autonomic function, and provided a blood sample.
2.2.4. Quarterly follow-up questionnaires and second clinic visit—At quarterly 
(i.e., three-monthly) intervals after baseline, participants completed a questionnaire that 
included a single question about headache frequency: “In the last 30 days, how many 
headaches of any type have you had?” and they recorded a number or marked “Don’t know.” 
The questionnaire also asked about TMD symptoms, and those responding positively were 
invited to return to study site clinics for a follow-up examination. Before the second clinic 
visit, questionnaires used at enrollment were mailed for completion at home, including the 
CPSQ that was used to classify headache again. During the second clinic visit, examiners 
used the same RDC/TMD criteria, and incident TMD was classified when examiners 
classified myalgia and/or arthralgia.
Follow-up data collection continued for each participant until clinical TMD was classified or 
until censoring (i.e., the study closeout date of May 31, 2011, or, for people lost to follow-
up, the date of the final follow-up questionnaire).
2.2.5. Nested case-control study of TMD incidence—As each incident TMD case 
was identified, one TMD-free control was sampled at random from the cohort and invited to 
visit the study site clinic for follow-up data collection. This included the CPSQ and the 
RDC/TMD examination to verify absence of clinical TMD. Controls were selected to match 
cases according to study site, gender, and time-in-study [56].
2.3. Variables used in this analysis
For demographic group comparisons, responses to the screening interview were used to 
create three age groups (18–24, 25–34, and 35–44 years), two genders (male, female), and 
five race-ethnicity groups (White, African-American, Hispanic, Asian, and Other).
For headache data collection, CPSQ questions were based on the diagnostic criteria 
specified in the 2nd edition of the International Classification of Headache Disorders 
(ICHD-2) [21] which was current when the OPPERA project began (Supplementary Table 
1). However, for this publication, we developed a new algorithm that, to the extent possible, 
used responses from the existing CPSQ questions to classify study participants according to 
the latest ICHD-3 beta criteria [1]. This algorithm updates the one used previously in the 
OPPERA study [49] for a three-level classification of headache. The current algorithm is 
restricted to classification of only primary headaches; an adequate inquiry to exclude 
secondary headaches of all causes was not part of the CPSQ. Self-reported headaches were 
classified into one of 7 types: no headache, unclassified headache, probable tension-type 
headache (TTH), definite TTH, probable migraine, definite migraine, and mixed headache. 
The “no headache” type comprised participants who did not report any headache in the 
preceding year. “Unclassified headache” included participants who reported headache in the 
last year but did not provide a complete set of data necessary for classification in the other 
types or did not meet the minimum ICHD criteria for even probable TTH or migraine. 
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“Probable TTH” was determined when all but one ICHD criterion for TTH were satisfied, 
and “definite TTH” was identified when all ICHD criteria for TTH were met. As migraine 
with aura is difficult to determine by questionnaire [58], migraine classification was limited 
to migraine without aura. “Probable migraine” was defined when all but one ICHD criterion 
for migraine without aura were fulfilled, and “definite migraine” was classified if all ICHD 
criteria for migraine without aura were met. When a single headache type met more than one 
set of criteria, classification was made according to the hierarchical sequence recommended 
by ICHD-3 beta [21], namely: precedence was given to definite migraine when all criteria 
were met for this headache type, then to definite TTH over probable migraine and probable 
TTH, and, finally, to probable migraine over probable TTH. When participants reported 
more than one type of headache among the three types that could be reported, a similar 
hierarchical approach was applied to these multiple classifications, except when ICHD 
criteria, for each of two headache types, were satisfied for both definite TTH and definite 
migraine without aura, in which case the classification was “mixed headache” 
(Supplementary Table 2). For some analyses, headache types were collapsed into 4 broader 
categories by combining 2 similar types together, e.g., probable migraine and definite 
migraine were combined into a category of “migraine.”
For analysis of TMD incidence, the binary outcome variable was the clinical classification 
of incident TMD, and time-in-study was measured in days as the period from baseline to 
either censoring or the visit when incident TMD was classified.
2.4 Test-retest reliability of headache classification
The test-retest reliability of the headache classification was assessed in a separate 
methodological study in which the CPSQ questionnaire was administered twice to each of 
108 study participants. These participants were selected from the OPPERA baseline case-
control study based on either presence (n=52) or absence of chronic TMD (n=56). The 
median interval between questionnaire administrations was 3 days (range = 1 to 8 days). 
Given that there are 250 data items in the CPSQ, we reasoned that this interval represented a 
sufficient period for participants to avoid recalling their first set of answers while 
minimizing the possibility that their symptom status of any type might change. The 
algorithm described above was used to make six binary classifications, one for each type of 
ICHD headache. Kappa values of test-retest reliability for the binary classifications ranged 
from 0.50 (migraine) to 0.54 (TTH). The weighted kappa statistic for the 7-category 
hierarchical headache classification was 0.62. These all represent acceptable reliability [14]. 
The exception was the binary classification of mixed headache where the kappa value of 
0.33 signified poor reliability. Kappa for the binary classification of any headache was 0.81 
indicating excellent reliability for this global classification.
2.5. Statistical methods
Data from baseline and follow-up were used to address the descriptive objectives of the 
study. At baseline, annual TMD incidence rate were calculated for all participants and for 
each demographic group, headache category, and headache frequency. The annual TMD 
incidence rate was calculated as the number of participants with first-onset TMD divided by 
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person-years of follow-up. It was estimated using a Poisson regression model that adjusted 
for OPPERA study site.
The second aim was addressed using data from baseline and quarterly follow-up 
questionnaires in the prospective cohort study. Because there were censored observations 
and different follow-up periods, Cox proportional hazard models were used to evaluate 
contributions of headache to risk of developing first-onset TMD. Repeated measurements of 
headache frequency in quarterly questionnaires were analyzed as time-varying covariates, 
and the effects of time were investigated using two strategies for time-to-event data [4]:
1. In the concurrent method, the time-varying predictor variable was headache 
frequency reported in the questionnaire completed at the same quarterly follow-
up at which time and censoring status (i.e., TMD incidence) were recorded. For 
the last quarter among incident cases, the 30-day reference period of the 
headache frequency question overlapped the 30-day reference period used to 
determine clinical TMD at that follow-up. This creates potential for reverse 
causation (i.e., clinical TMD causing headache).
2. The “lagged” method addresses that problem by using headache frequency 
reported in the questionnaire that preceded the quarter used in the concurrent 
method. Because all participants, including incident cases, were TMD-free in the 
lagged quarter, this variable precludes the possibility of reverse causation.
Separate Cox models were created for each method, and each model included time-constant 
covariates of demographics and study site. Overall model fit was judged using the likelihood 
ratio test, while effects of individual predictors were quantified as hazard ratios and their 
95% confidence interval (95% CI). In these models, time-varying headache frequency was 
transformed from the count of headaches to z-scores. This allowed hazard ratios to be 
interpreted consistently as the relative effect on the TMD incidence rate associated with a 
one standard deviation increase in headache frequency. Because lagged quarters could be 
computed only for participants who completed at least two quarterly follow-up 
questionnaires, all models were limited to participants who completed ≥2 follow-up 
questionnaires.
Follow-up data from the nested case-control study were used to address the third aim of the 
study. Headache frequency was plotted at four time points: 1) the first quarter; 2) 
intermediate quarters, defined as follow-up questionnaires completed after the first quarter 
but before the penultimate quarter; 3) the penultimate quarter, defined as the follow-up 
questionnaire completed three months before the final quarter; and 4) the final quarter, 
terminated by TMD onset or censoring. At each time point, mixed models for repeated 
measures were used to estimate odds of reporting any headache vs. none and the mean 
number of headaches per month. Predictor variables were time (4 categories), incident TMD 
case-classification (two categories), and their two-way interaction. Covariates were study 
site and the demographic characteristics. Changes in headache types were analyzed using 
data from the CPSQ completed at baseline and the follow-up in the nested case-control 
study. Contingency tables cross-classified study participants according to the seven headache 
types reported at baseline and follow-up. The degree of change was expressed as the 
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percentage of participants whose headache type had changed, and Bowker’s test of 
symmetry for matched data (baseline and follow-up) was used to evaluate the null 
hypothesis of no change.
When headache types were collapsed to dichotomies, the degree of change was expressed as 
the odds ratio for matched pairs and McNemar’s test was used to evaluate the null 
hypothesis of no change. This was done separately for incident TMD cases and controls 
using three dichotomies of headache types for each group. The dichotomies were based on 
the following thresholds, with the hierarchically-lower types of headache than the named 
type in each dichotomy forming the comparison group: a) probable TTH or worse (any 
ICHD-classified headache disorder), b) definite TTH or worse, and c) probable migraine or 
worse. The odds ratio represents the odds of headache at follow-up relative to baseline. Odds 
ratios exceeding 1.0 signify a net increase in occurrence at follow-up relative to baseline, 
whereas odds ratios less than 1.0 signify a net decrease in occurrence. For clarity, we 
therefore use the label “progression/remission” to describe this odds ratio, emphasizing that 
it quantifies temporal changes in headache over time, not an association between headache 
and incident TMD case status. Specifically, “progression” refers to a headache transition to 
any hierarchically-higher type, while “remission” refers to a change to any hierarchically-
lower type including complete absence of headache. All analyses were performed using 
SAS, version 9.3(NC, USA).
2.5. Sample size justification
In the OPPERA prospective cohort study, the target sample size of 3,200 enrollees was 
expected to yield 196 first-onset TMD cases during a three-year follow-up period. 
Calculations made when designing the study indicated that those numbers would provide 
80% statistical power to detect risk ratios of at least 1.8 for risk predictors with as few as 
15% of people in the high-risk category [6].
3. Results
3.1. Characteristics of participants
Of 3,263 enrollees in the prospective cohort study, 2,410 participants provided at least two 
follow-up questionnaires, completing a median of 10 quarterly follow-up questionnaires 
during follow-up periods ranging from 0.34 to 5.2 years (Supplementary Figure 1). At 
follow-up examinations, 199 participants had examiner-verified TMD, representing an 
average incidence rate of TMD of 2.8% per year (Table 1). Although the incidence rate did 
not vary appreciably among demographic groups, it differed among categories of baseline 
headache and categories of headache frequency. Based on non-overlap of 95% CIs, the TMD 
incidence rate was higher for mixed headache (8.4% per year) and for a headache frequency 
category of 4 headaches per month (6.0% per year).
In the nested case-control study, there were 248 incident TMD cases and 191 TMD-free 
controls (Table 1). The number of incident cases in the nested case-control study is larger 
than analyzed for the prospective cohort study because additional cases that provided less 
than two valid follow-up questionnaires were included in the analysis for the case-control 
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study. While cases and controls did not differ appreciably in distribution of demographic 
characteristics, migraine at baseline occurred more commonly in cases than controls. 
Likewise, cases were about twice as likely as controls to report 3 or 4 headaches per month 
at baseline. For mixed models presented in Figure 1, data analysis was restricted to 361 
participants (196 incident TMD cases and 165 TMD-free controls) who completed at least 
two follow-up questionnaires and provided a valid report of headache frequency.
3.2. Headache as a risk factor for first-onset TMD in the prospective cohort study
Among the 2,410 participants in the prospective cohort study, headache at baseline was a 
significant predictor of TMD incidence (Table 2). Of the 4 baseline headache categories, 
migraine and mixed headache were significant predictors of TMD incidence in Model 1 
(HR=1.67, 95% CI: 1.06, 2.62; and HR=4.11, 95% CI: 1.47, 11.46; respectively). When 
baseline headache frequency was instead used as the predictor, there was a dose-response 
gradient of HRs which increased monotonically from 1.11 (95% CI: 0.76, 1.63), for those 
with 1 headache per month, to 3.09 (95% CI: 1.94, 4.94), for those with 4 headaches per 
month. Addition of time-varying headache frequency calculated using the concurrent quarter 
dramatically increased the chi-square statistic of model fit from 74.3 (Model 2) to 263.5 
(Model 3) and the corresponding hazard ratio for concurrent time-varying headache 
frequency was statistically significant (HR=1.53, 95% CI: 1.46, 1.6; Model 3). When lagged 
time-varying headache frequency was instead added to Model 2 in order to avoid potential 
for reverse causation, it too was a significant predictor (HR=1.36, 95% CI: 1.28, 1.45; 
Model 4).
3.3. Headache contribution to developing first-onset TMD in the nested case-control study 
of incident TMD cases and TMD-free controls
The temporal patterns in headache prevalence during follow-up in the nested case-control 
study differed between incident TMD cases and controls (Figure 1A). The mixed model 
used to evaluate those temporal patterns revealed significant main effects of case status 
(P<0.0001) and time (P=0.007), and their interaction (P<0.0001). Relative to TMD-free 
controls, incident TMD cases were more likely to report a headache at all four time points 
prior to the TMD onset (Figure 1A). When contrasts were performed to compare headache 
prevalence at each time point within TMD and control groups, the prevalence of headache 
was significantly greater among TMD cases at the last quarter (94%) relative to the first 
quarter (79%), while the prevalence among controls did not differ across all four time points 
(50–60%).
In the mixed model evaluating the temporal patterns in number of headaches per month, 
there were likewise significant main effects of case status (P<0.0001) and time (P<0.0001), 
and their interaction (P<0.0001). Relative to controls, incident TMD cases reported 
significantly (P≤0.0002) higher frequency of headache at all four time points prior to the 
TMD onset (Figure 1B). When contrasts were performed to compare headache frequency at 
each time point within TMD and control groups, headache frequency was greater among 
TMD cases at the penultimate and last quarters relative to the first quarter, while it did not 
differ across all four time points for controls. For TMD cases, headache frequency increased 
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from 3 headaches per month at the first quarter to 7 headaches per months at the last quarter, 
while for controls headache frequency stayed around 1 headache per month.
3.4. Dynamic patterns of headache type change during follow-up in the nested case-
control study
Results of baseline and follow-up headache classification for incident TMD cases and TMD-
free controls participating in the nested case-control study (n=439) are presented in Table 3. 
In controls, the percentage reporting no headache decreased by one third, from 28.8% to 
19.9%, whereas in TMD cases, it reduced by two thirds, from 20.2% to 6.5%. Meanwhile, 
the prevalence of any migraine in controls increased marginally, from 8.4% to 12.0%, 
whereas in TMD cases, it nearly doubled, from 16.1% to 28%. The most dramatic escalation 
was noted in prevalence of definite migraine, which increased nearly ten-fold from 1.2% to 
9.7% among TMD cases.
The more detailed investigation of headache types across the follow-up periods revealed 
markedly different patterns of headache change in TMD cases compared to controls (Figure 
2A). In comparison to TMD cases, a much higher percentage of controls with no headache 
at baseline remained headache-free at follow-up (14.7% vs. 3.6% for the cases). Progression 
to any migraine was observed from all hierarchically-lower types of headache and was 
greater for TMD cases relative to controls: from no headache, 4.4% vs.1%; from 
unclassified headache, 2.4% vs. 0%; from probable TTH, 4.4% vs. 1.6%; and from definite 
TTH, 7.6% vs. 5.2%.
Differences between TMD cases and controls became more notable when the same data 
were reduced to three possible patterns of change that assumed a gradient of severity across 
headache types (Figure 2B). In general, controls showed greater stability in headache types 
relative to TMD cases. Specifically, classification of probable TTH was stable in 10.5% of 
controls vs. 3.6% of TMD cases, classification of definite TTH was stable in 19.4% of 
controls vs. 12.9% of TMD cases, and classification of probable migraine was similarly 
stable in both groups (3.1% of controls vs. 4.6% of TMD cases). Due to the small number of 
cases meeting criteria for definite migraine and for mixed headache at baseline, their degree 
of stability or change could not be precisely quantified. Another general trend was a greater 
tendency for headache “worsening” (i.e., progression) among TMD cases compared to 
controls, regardless of the type of headache at baseline. Specifically, baseline unclassified 
headache worsened in 7.7% of TMD cases vs. 2.6% of controls, probable TTH worsened in 
13.7% of TMDs vs. 8.4% of controls, definite TTH worsened in 8.1% of TMDs vs. 5.8% of 
controls, and probable migraine worsened in 4% of TMDs vs. 1% of controls. The overall 
statistical significance of these temporal changes was confirmed using Bowker’s test of 
symmetry for matched contingency tables which revealed a significant degree of change 
among incident TMD cases (chi-square=99.7, P<0.0001) but not among TMD-free controls 
(chi-square=19.2, P>0.05).
When change was investigated for binary categories of headache using the three different 
thresholds as cut-points, as described under data analysis, incident TMD cases had 
statistically significant increases for all three thresholds of dichotomizing the headache 
hierarchy (P≤0.002, Table 4), with progression/remission odds ratios ranging from 1.9 (95% 
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CI: 1.2, 2.8) for definite TTH threshold to 2.8 (95% CI: 1.6, 4.8) for probable migraine 
threshold. In contrast, among TMD-free controls, there was significant change only at a 
threshold of definite TTH, with a progression/remission odds ratio of 2.1 (95% CI: 1.2, 3.9; 
Table 4).
4. Discussion
In this 5-year prospective study, we found that baseline reports of migraine, mixed headache, 
or headache frequency predicted increased risk of developing TMD. Both headache 
prevalence and frequency increased across the observation period among those who 
developed TMD but not among matched controls. Although patterns of change were 
complex when multiple types of headache were considered, incident cases of TMD were 
more likely to experience worsening in headache type and less likely to experience 
improvement compared to matched controls. For TMD cases, the most striking change was 
observed in prevalence of definite migraine which increased ten-fold. Among all headache 
types experienced by TMD cases, migraine had the highest progression/remission odds ratio, 
while increased likelihood of progression for controls emerged only for TTH.
The 1-year prevalence of 10.3% for migraine and 54.4 % for TTH reported in this study is 
similar to the previously published estimates [26,57]. For example, a recent population-
based American Migraine Prevalence and Prevention study found 11.7% prevalence for 
migraine (17.1% in women and 5.6% in men) among individuals aged 12 years and older 
[34]. While assessments of migraine prevalence are remarkably stable across different 
populations, the estimates of TTH prevalence vary widely between studies, depending of 
case definition, sampling procedures, and data collection methodology [46]. The largest 
American study reporting data on TTH prevalence observed the 1-year prevalence of 38.3%, 
peaking in the fourth decade of life in both women (46.9%) and men (42.3%) [53]. In 
contrast, the largest European study conducted in Denmark demonstrated the 1-year 
prevalence of 86.0% (92.5% in women and 78.9% in men) [47].
Although many studies demonstrate an association between TMD and headache, the 
underlying reasons for this association are poorly understood. It might be that people with 
TMD have another pathophysiologic condition or predisposition leading to both TMD and 
headache; that TMD causes headache; or that headache causes TMD. Obstructive sleep 
apnea might serve as an example of the first scenario, because it was associated both with 
TMD onset [48] and morning headache [15]. The second scenario can be illustrated by 
headache attributed to TMD, a secondary headache newly redefined by recent research [50] 
and recognized by the ICHD-3 beta [1]. While all three scenarios are plausible, the current 
study – because of its prospective design – provides evidence for the last option: headache as 
a cause of TMD.
Our finding that migraine but not TTH was a risk factor for incident TMD is especially 
intriguing because TMD traditionally is thought to be associated with TTH [59]. Supporting 
our results, higher migraine disability assessment (MIDAS) scores were positively 
associated with masticatory and cervical myalgia in a study of orofacial pain patients [10]. 
In addition, a few case-control studies reported association between migraine and TMD in 
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adults [17,18] and children [32]. However, others found no difference in TMD prevalence 
between headache groups [7,52], although none of the previous studies of adults assessed 
the impact of various headache types on TMD onset in a prospective design. The association 
between migraine and TMD may be due to multiple biopsychosocial factors, such as shared 
physiology, genetics, psychological traits, and environmental influences. Both migraine and 
TMD pain are mediated by the trigeminocervical complex [16,19] and migraine-specific 
sensitization of trigeminal nociception [28] is likely to facilitate the onset of TMD. 
Dysregulation of pain modulatory mechanisms in the central and peripheral nervous systems 
has been reported in both conditions [3,33,38,43]. Disrupted central modulation in migraine 
is supported by neuroimaging studies which demonstrated that activation of specific 
brainstem areas occurred not only during the migraine attacks but persisted after successful 
treatment [61]. This long-lasting alteration in central pain processing may be another 
mechanism contributing to incidence of TMD. On the other hand, the extent to which 
migraine and TMD share common genetic risks appears only modest: a recent twin study 
revealed that only 12% of the genetic component of TMD pain is shared with migraine [45]. 
In contrast, among psychological factors, depression and anxiety are consistently reported as 
risk factors for both migraine and TMD [2,13,20,30]. In addition, behavioral factors, such as 
stress, can also contribute to the pathogenesis of both conditions [13,23].
This study for the first time identified headache frequency as a significant predictor of TMD 
onset. This is consistent with previous case-control studies reporting an association between 
headache frequency and severity of TMD pain in adults [18] and higher TMD scores in 
children [32]. In addition, headache frequency was substantially correlated with reduced 
physical and emotional functioning and aggravation of TMD symptoms in TMD patients 
with temple headache [5,35].
The observed temporal fluidity of headache types underscores the importance of using 
prospective studies when investigating patterns and consequences of headache. The existing 
evidence suggests substantial change, not temporal stability, in predominant headache types. 
In a 12-year prospective Danish population-based study, 42% of participants with migraine 
and 45% of participants with previous frequent episodic TTH experienced remission at 
follow-up, while 20% of participants with migraine and 16% of TTH sufferers developed 
chronic severe headaches [36]. In a 30-year prospective Swiss cohort study, only 21% of 
people with migraine and 7% of those with TTH continued to have the same headache for 
more than half of the follow-up period [39]. A bi-directional crossover of 20–25% between 
migraine and TTH was reported in a 7-year prospective study of a clinical sample of 
children and adolescents [29]. Our results showed similar complex headache patterns and 
demonstrated that, among those patterns, progression to migraine was the most essential 
factor distinguishing between Incident TMD cases and controls. The important implication 
of this finding for clinical care is that screening, thorough monitoring, and adequate 
treatment of migraine should be implemented as a preventive strategy for reducing the risk 
of development of TMD.
The present study had several strengths. To our knowledge, it is the first large prospective 
cohort study examining the role of headache in first-onset TMD in adults. Second, the 
prospective design of the study established the temporal relationship between headache and 
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the first onset of TMD, thereby satisfying a prominent criterion for causal inference and 
supporting our conclusion that headache is a cause of TMD. Specifically, headache type was 
determined at baseline, when all study participants were free from TMD. Third, the use of a 
standardized RDC/TMD clinical examination and a reliable headache questionnaire 
permitted consistent classification of both conditions. Fourth, we employed very frequent 
(quarterly) follow-up surveys which allowed recurrent assessment of headache frequency as 
well as very precise ascertainment of the time of TMD onset, while eliminating the 
possibility of reverse causation. Only one previous study investigating TMD onset in early 
adolescence used such short follow-up intervals [31]. Fifth, our nested case-control study 
permitted a direct comparison of dynamic headache patterns among incident TMD cases and 
TMD-free controls.
However, this study had several limitations. First, as in any prospective cohort study, there 
was loss to follow-up although, as reported elsewhere [6]; this loss was non-differential, i.e., 
the degree of the loss generally did not differ in groups classified by a range of TMD risk 
factors. Second, because participants with 5 or more headaches per month were excluded 
from enrolling in the study, this criterion could have led to overly-conservative estimates of 
impact of headache frequency on TMD onset. While inclusion of individuals with higher 
headache frequency might have revealed a greater influence of headache on risk of TMD 
onset, we feared it would mask signs and symptoms of underlying TMD, with the 
consequence of inadvertent enrollment of TMD cases. Third, headache types were classified 
only by questionnaire whilst a clinical assessment by a specialist and use of daily diaries 
would be more valid. Unfortunately, this approach is difficult to employ in a large-scale 
epidemiologic study. Fourth, we couldn’t classify medication-overuse headache as detailed 
data on analgesic use were not collected in the study. Finally, the external validity of study 
estimates could be limited because study participants were not selected at random from the 
community. However, the participants were recruited from 4 geographically distant study 
sites using multiple recruitment strategies, thereby providing good representation of major 
US demographic groups [54].
In summary, these data support the hypothesis that migraine and frequent headaches 
contribute to risk of developing TMD. Future studies should address the question if timely 
and optimal migraine therapy could reduce the risk of TMD onset.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Headache characteristics at four time points prior to follow-up visit for incident TMD cases 
(●) and TMD-free controls (○) in the OPPERA nested case-control study (n=361): (1A) 
headache quarterly prevalence and (1B) adjusted means for headache monthly frequency 
were calculated from mixed models. Asterisks denote statistically significant difference 
(P<0.0001) between the first quarter and subsequent time points for TMD cases. TMD cases 
significantly differed from controls at all time points (P<0.0001 for headache prevalence and 
P≤0.0002 for headache frequency).
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Temporal dynamics of headache for incident TMD cases and TMD-free controls in the 
OPPERA nested case-control study (n=439). (2A) Distribution of headache types at follow-
up visit in TMD cases and controls. Denominator for percentages of TMD cases is n=248 
subjects who developed TMD between baseline and follow-up. Denominator for percentages 
of controls is n=191 subjects who remained TMD-free at baseline and follow-up. (2B) The 
same data from 2A with patterns of change between baseline and follow-up collapsed to 
signify worsening, no change, or improvement in headache types. Abbreviations: TMD = 
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temporomandibular disorder, C = TMD-free controls, HA = headache, MIG = migraine, 
TTH = tension-type headache, Prob. = probable.
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Table 3
Headache classification at baseline and follow-up in the OPPERA nested case-control study (n = 439)
Headache classification
TMD cases: number of subjects (column %) TMD-free controls: number of subjects (column %)
Baseline Follow-up Baseline Follow-up
No headache 50 (20.2) 16 (6.5) 55 (28.8) 38 (19.9)
Unclassified headache 25 (10.1) 32 (12.9) 7 (3.7) 13 (6.8)
Any TTH 129 (52.0) 124 (50.0) 109 (57.1) 114 (59.7)
 Probable TTH 55 (22.2) 51 (20.6) 48 (25.1) 42 (22.0)
 Definite TTH 74 (29.8) 73 (29.4) 61 (31.9) 72 (37.7)
Any migraine 40 (16.1) 71 (28.6) 16 (8.4) 23 (12.0)
 Probable migraine 37 (14.9) 47 (19.0) 15 (7.9) 20 (10.5)
 Definite migraine 3 (1.2) 24 (9.7) 1 (0.5) 3 (1.6)
Mixed headache 4 (1.6) 5 (2.0) 4 (2.1) 3 (1.6)
Abbreviations: TTH = tension-type headache, TMD = temporomandibular disorder.
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Table 4
Variation among TMD cases and TMD-free controls in headache prognosis measured at dichotomized 
headache categories in the OPPERA nested case-control study (n = 439)
Dichotomized headache categories









remission OR (95% 
CI)
Any classified headache vs. the rest 9.7 (0.002) 2.1 (1.3, 3.5) 2.6 (0.109) 1.6 (0.9, 2.9)
Definite TTH and worse vs. the rest 9.3 (0.002) 1.9 (1.2, 2.8) 6.1 (0.013) 2.1 (1.2, 3.9)
Probable migraine and worse vs. the rest 15.1 (0.0001) 2.8 (1.6, 4.8) 1.4 (0.239) 1.6 (0.7, 3.5)
Abbreviations: TTH = tension-type headache, TMD = temporomandibular disorder, OR = odds ratio, 95% CI = 95% confidence interval.
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